Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Angiotensin II Type 1 Receptor Antagonist Azilsartan Restores Vascular Reactivity Through a Perivascular Adipose Tissue-Independent Mechanism in Rats with Metabolic Syndrome.

Kagota S, Maruyama-Fumoto K, Shimari M, McGuire JJ, Shinozuka K.

Cardiovasc Drugs Ther. 2019 Aug 16. doi: 10.1007/s10557-019-06900-1. [Epub ahead of print]

PMID:
31420755
2.

Betaglycan drives the mesenchymal stromal cell osteogenic program and prostate cancer-induced osteogenesis.

Cook LM, Frieling JS, Nerlakanti N, McGuire JJ, Stewart PA, Burger KL, Cleveland JL, Lynch CC.

Oncogene. 2019 Aug 13. doi: 10.1038/s41388-019-0913-4. [Epub ahead of print]

PMID:
31409900
3.

Endothelium-dependent impairments to cerebral vascular reactivity with type 2 diabetes mellitus in the Goto-Kakizaki rat.

Halvorson BD, Whitehead SN, McGuire JJ, Wiseman RW, Frisbee JC.

Am J Physiol Regul Integr Comp Physiol. 2019 Jul 1;317(1):R149-R159. doi: 10.1152/ajpregu.00088.2019. Epub 2019 May 15.

PMID:
31091154
4.

Perivascular Adipose Tissue-Enhanced Vasodilation in Metabolic Syndrome Rats by Apelin and N-Acetyl⁻l-Cysteine-Sensitive Factor(s).

Kagota S, Maruyama-Fumoto K, Iwata S, Shimari M, Koyanagi S, Shiokawa Y, McGuire JJ, Shinozuka K.

Int J Mol Sci. 2018 Dec 28;20(1). pii: E106. doi: 10.3390/ijms20010106.

5.

Progression of Time-Dependent Changes to the Mechanisms of Vasodilation by Protease-Activated Receptor 2 in Metabolic Syndrome.

Maruyama K, McGuire JJ, Kagota S.

Biol Pharm Bull. 2017;40(12):2039-2044. doi: 10.1248/bpb.b17-00343. Review.

6.

Intrauterine growth-restricted Yucatan miniature pigs experience early catch-up growth, leading to greater adiposity and impaired lipid metabolism as young adults.

Myrie SB, McKnight LL, King JC, McGuire JJ, Van Vliet BN, Cheema SK, Bertolo RF.

Appl Physiol Nutr Metab. 2017 Dec;42(12):1322-1329. doi: 10.1139/apnm-2017-0311. Epub 2017 Aug 16.

PMID:
28813611
7.

Time-Dependent Differences in the Influence of Perivascular Adipose Tissue on Vasomotor Functions in Metabolic Syndrome.

Kagota S, Iwata S, Maruyama K, McGuire JJ, Shinozuka K.

Metab Syndr Relat Disord. 2017 Jun;15(5):233-239. doi: 10.1089/met.2016.0146. Epub 2017 Mar 30.

PMID:
28358621
8.

Cardiac expression of ryanodine receptor subtype 3; a strategic component in the intracellular Ca2+ release system of Purkinje fibers in large mammalian heart.

Daniels RE, Haq KT, Miller LS, Chia EW, Miura M, Sorrentino V, McGuire JJ, Stuyvers BD.

J Mol Cell Cardiol. 2017 Mar;104:31-42. doi: 10.1016/j.yjmcc.2017.01.011. Epub 2017 Jan 20.

PMID:
28111173
9.

Age-related changes to vascular protease-activated receptor 2 in metabolic syndrome: a relationship between oxidative stress, receptor expression, and endothelium-dependent vasodilation.

Maruyama K, Kagota S, McGuire JJ, Wakuda H, Yoshikawa N, Nakamura K, Shinozuka K.

Can J Physiol Pharmacol. 2017 Apr;95(4):356-364. doi: 10.1139/cjpp-2016-0298. Epub 2016 Oct 19.

PMID:
28103056
10.

Characterization and Functions of Protease-Activated Receptor 2 in Obesity, Diabetes, and Metabolic Syndrome: A Systematic Review.

Kagota S, Maruyama K, McGuire JJ.

Biomed Res Int. 2016;2016:3130496. doi: 10.1155/2016/3130496. Epub 2016 Feb 23. Review.

11.

[Role/function of protease-activated receptor 2 on vascular endothelium in metabolic syndrome].

Maruyama K, McGuire JJ, Shinozuka K, Kagota S.

Nihon Yakurigaku Zasshi. 2016 Mar;147(3):135-8. doi: 10.1254/fpj.147.135. Japanese. No abstract available.

PMID:
26960771
12.

Enhanced Nitric Oxide Synthase Activation via Protease-Activated Receptor 2 Is Involved in the Preserved Vasodilation in Aortas from Metabolic Syndrome Rats.

Maruyama K, Kagota S, McGuire JJ, Wakuda H, Yoshikawa N, Nakamura K, Shinozuka K.

J Vasc Res. 2015;52(4):232-43. doi: 10.1159/000442415. Epub 2016 Jan 14.

PMID:
26760532
13.

Corrigendum: Greenland supraglacial lake drainages triggered by hydrologically induced basal slip.

Stevens LA, Behn MD, McGuire JJ, Das SB, Joughin I, Herring T, Shean DE, King MA.

Nature. 2015 Sep 3;525(7567):144. doi: 10.1038/nature14608. Epub 2015 Jul 1. No abstract available.

PMID:
26131938
14.

Greenland supraglacial lake drainages triggered by hydrologically induced basal slip.

Stevens LA, Behn MD, McGuire JJ, Das SB, Joughin I, Herring T, Shean DE, King MA.

Nature. 2015 Jun 4;522(7554):73-6. doi: 10.1038/nature14480. Erratum in: Nature. 2015 Sep 3;525(7567):144.

PMID:
26040890
15.

Small caliber arterial endothelial cells calcium signals elicited by PAR2 are preserved from endothelial dysfunction.

Hennessey JC, Stuyvers BD, McGuire JJ.

Pharmacol Res Perspect. 2015 Mar;3(2):e00112. doi: 10.1002/prp2.112.

16.

Disturbance of vasodilation via protease-activated receptor 2 in SHRSP.Z-Lepr fa/IzmDmcr rats with metabolic syndrome.

Kagota S, Maruyama K, Wakuda H, McGuire JJ, Yoshikawa N, Nakamura K, Shinozuka K.

Vascul Pharmacol. 2014 Oct;63(1):46-54. doi: 10.1016/j.vph.2014.06.005. Epub 2014 Aug 7.

PMID:
25109437
17.

Effects of chronic in-vivo treatments with protease-activated receptor 2 agonist on endothelium function and blood pressures in mice.

Hughes KH, Wijekoon EP, Valcour JE, Chia EW, McGuire JJ.

Can J Physiol Pharmacol. 2013 Apr;91(4):295-305. doi: 10.1139/cjpp-2012-0266. Epub 2012 Dec 19.

18.

Attenuated vasodilator effectiveness of protease-activated receptor 2 agonist in heterozygous par2 knockout mice.

Hennessey JC, McGuire JJ.

PLoS One. 2013;8(2):e55965. doi: 10.1371/journal.pone.0055965. Epub 2013 Feb 7.

19.
20.

Geophysics. A rogue earthquake off Sumatra.

McGuire JJ, Beroza GC.

Science. 2012 Jun 1;336(6085):1118-9. doi: 10.1126/science.1223983. Epub 2012 May 10. No abstract available.

PMID:
22582017
21.

Protection of protease-activated receptor 2 mediated vasodilatation against angiotensin II-induced vascular dysfunction in mice.

Chia E, Kagota S, Wijekoon EP, McGuire JJ.

BMC Pharmacol. 2011 Sep 28;11:10. doi: 10.1186/1471-2210-11-10.

22.

Preserved arterial vasodilatation via endothelial protease-activated receptor-2 in obese type 2 diabetic mice.

Kagota S, Chia E, McGuire JJ.

Br J Pharmacol. 2011 Sep;164(2):358-71. doi: 10.1111/j.1476-5381.2011.01356.x.

23.
24.

Protease-activated receptor 2 and bradykinin-mediated vasodilation in the cerebral arteries of stroke-prone rats.

Smeda JS, McGuire JJ, Daneshtalab N.

Peptides. 2010 Feb;31(2):227-37. doi: 10.1016/j.peptides.2009.11.026. Epub 2009 Nov 30.

PMID:
19954757
25.

Inhibition of human folylpolyglutamate synthetase by diastereomeric phosphinic acid mimics of the tetrahedral intermediate.

McGuire JJ, Bartley DM, Tomsho JW, Haile WH, Coward JK.

Arch Biochem Biophys. 2009 Aug 15;488(2):140-5. doi: 10.1016/j.abb.2009.06.017. Epub 2009 Jun 27. Erratum in: Arch Biochem Biophys. 2010 Jan 15;493(2):250.

26.

Developmental programming of lipid metabolism and aortic vascular function in C57BL/6 mice: a novel study suggesting an involvement of LDL-receptor.

Chechi K, McGuire JJ, Cheema SK.

Am J Physiol Regul Integr Comp Physiol. 2009 Apr;296(4):R1029-40. doi: 10.1152/ajpregu.90932.2008. Epub 2009 Feb 4. Erratum in: Am J Physiol Regul Integr Comp Physiol. 2009 Sep;297(3):R911.

27.

Metabolism-blocked antifolates as potential anti-rheumatoid arthritis agents: 4-amino-4-deoxy-5,8,10-trideazapteroyl-d,l-4'-methyleneglutamic acid (CH-1504) and its analogs.

McGuire JJ, Haile WH.

Biochem Pharmacol. 2009 Apr 1;77(7):1161-72. doi: 10.1016/j.bcp.2008.12.020. Epub 2009 Jan 6.

PMID:
19174154
28.
29.
30.

Design and synthesis of classical and nonclassical 6-arylthio-2,4-diamino-5-ethylpyrrolo[2,3-d]pyrimidines as antifolates.

Gangjee A, Zeng Y, Talreja T, McGuire JJ, Kisliuk RL, Queener SF.

J Med Chem. 2007 Jun 28;50(13):3046-53. Epub 2007 Jun 7.

31.
32.

Persistence of PAR-2 vasodilation despite endothelial dysfunction in BPH/2 hypertensive mice.

McGuire JJ, Van Vliet BN, Giménez J, King JC, Halfyard SJ.

Pflugers Arch. 2007 Jul;454(4):535-43. Epub 2007 Feb 23.

PMID:
17318644
33.
37.
38.
39.

Synthesis of (6R)- and (6S)-5,10-dideazatetrahydrofolate oligo-gamma-glutamates: kinetics of multiple glutamate ligations catalyzed by folylpoly-gamma-glutamate synthetase.

Tomsho JW, McGuire JJ, Coward JK.

Org Biomol Chem. 2005 Sep 21;3(18):3388-98. Epub 2005 Aug 15. Erratum in: Org Biomol Chem. 2005 Oct 21;3(20):3825.

40.
41.

Foreshock sequences and short-term earthquake predictability on East Pacific Rise transform faults.

McGuire JJ, Boettcher MS, Jordan TH.

Nature. 2005 Mar 24;434(7032):457-61. Erratum in: Nature. 2005 May 26;435(7041):528.

PMID:
15791246
42.

Hyperpolarization of murine small caliber mesenteric arteries by activation of endothelial proteinase-activated receptor 2.

McGuire JJ, Hollenberg MD, Bennett BM, Triggle CR.

Can J Physiol Pharmacol. 2004 Dec;82(12):1103-12.

PMID:
15644953
43.

Synthesis of classical, three-carbon-bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates.

Gangjee A, Zeng Y, McGuire JJ, Mehraein F, Kisliuk RL.

J Med Chem. 2004 Dec 30;47(27):6893-901.

PMID:
15615538
45.
46.

The endothelium in health and disease--a target for therapeutic intervention.

Triggle CR, Hollenberg M, Anderson TJ, Ding H, Jiang Y, Ceroni L, Wiehler WB, Ng ES, Ellis A, Andrews K, McGuire JJ, Pannirselvam M.

J Smooth Muscle Res. 2003 Dec;39(6):249-67. Review.

47.

2-furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist.

McGuire JJ, Saifeddine M, Triggle CR, Sun K, Hollenberg MD.

J Pharmacol Exp Ther. 2004 Jun;309(3):1124-31. Epub 2004 Feb 19.

PMID:
14976230
48.

Anticancer antifolates: current status and future directions.

McGuire JJ.

Curr Pharm Des. 2003;9(31):2593-613. Review.

PMID:
14529544
49.

Recent advances in the chemistry and biology of folypoly-gamma-glutamate synthetase substrates and inhibitors.

Gangjee A, Dubash NP, Zeng Y, McGuire JJ.

Curr Med Chem Anticancer Agents. 2002 May;2(3):331-55. Review.

PMID:
12678736

Supplemental Content

Loading ...
Support Center